Ichiro Abe (2020) “Efficacy and safety of low-dose ipragliflozin, a selective sodium glucose transporter 2 inhibitor, in patients with type 2 diabetes mellitus”, International Journal of Allied Medical Sciences and Clinical Research, 4(3), pp. 376–382. doi: 10.61096/ijamscr.v4.iss3.2016.376-382.